MASP-3 Inhibitory Antibodies for Selective Complement Initiation Blockade
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current complement inhibitors primarily target downstream molecules, such as C5, which do not effectively inhibit the initiation of complement activation, leading to potential host tissue damage in various disease states, and there is a need for inhibitors that can specifically target the initiation steps of complement activation.
Innovation Solution
Development of a monoclonal antibody or antigen-binding fragment that specifically binds to the serine protease domain of human MASP-3 with high affinity, inhibiting the alternative pathway of complement activation without affecting the classical pathway, and reducing hemolysis and opsonization.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If downstream complement molecules like C5 are targeted for inhibition, then complement-mediated tissue damage is reduced, but the initiation of complement activation is not effectively inhibited
Solution Approach 1:
The patent extracts the inhibition target from downstream complement molecules (C5) to the upstream initiation molecule MASP-3. By specifically targeting MASP-3, the antibody prevents the initiation of the alternative complement pathway at its source, thereby reliably blocking complement activation while still allowing downstream effects to be controlled.
Solution Approach 2:
The patent applies preliminary action by inhibiting MASP-3, which acts before the full complement cascade is activated. By blocking MASP-3 at the initiation stage, the patent prevents subsequent activation of C3 and other downstream components, achieving reliable inhibition of complement-mediated damage before it fully develops.
2Object-affected harmful factors
If broad complement pathway inhibition is achieved, then tissue damage is reduced, but specificity in pathway inhibition is lost
Solution Approach 1:
The patent applies local quality by designing an antibody that specifically targets MASP-3 in the alternative pathway while leaving other complement pathways (classical and lectin) unaffected. This localized inhibition approach allows selective blockade of harmful alternative pathway activation without disrupting the functionality of other immune pathways.
Solution Approach 2:
The patent segments the complement system inhibition by targeting a specific component (MASP-3) rather than using broad-spectrum complement inhibitors. This segmentation enables selective inhibition of the alternative pathway while preserving classical and lectin pathway functions, providing adaptability in pathway-specific therapy.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antibody effectively inhibits alternative pathway complement activation, reducing hemolysis, C3 cleavage, and deposition of C3b on surfaces, thereby mitigating tissue damage associated with complement system activation in diseases like paroxysmal nocturnal hemoglobinuria and ischemia-reperfusion injury.
Implementation Method 1
an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds to the serine protease domain of human MASP-3 (amino acid residues 450 to 728 of SEQ ID NO:2) with high affinity (having a KD of less than 500 pM)
Data Source
AI summary
The present invention relates to MASP-3 inhibitory antibodies and compositions comprising such antibodies for use in inhibiting the adverse effects of MASP-3 dependent complement activation.